ALTHOUGH GSK's Bexsero (meningococcal B) vaccine is currently in short supply, the company has given assurances that Australians will be able to access the vaccine by the end of Jan, but does say the demand is still high.
First supplies will probably be quickly soaked up by back orders, but GSK says it will import five times the 2016 volume in 2017.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jan 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jan 17
